Medical Radiology and Radiation Safety. 2026. Vol. 71. № 2

DOI:10.33266/1024-6177-2026-71-2-81-92

B.Ya. Narkevich^{1, 2}

Is Dosimetry Necessary in Radionuclide Therapy of Patients with Metastases?

¹ N.N. Blokhin National Medical Research Center of Oncology, Moscow

² Association of Medical Physicists of Russia, Moscow

Contact person: B.Ya. Narkevich, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

Purpose: Analysis of modern approaches to dosimetric support of radionuclide therapy at the technological stages of dosimetric planning, hospitalization and evaluation of treatment effectiveness.

Material and methods: A comparative analysis of the methodological specifics of dosimetric support of radionuclide therapy with the introduction of radiopharmaceuticals into the body and conventional radiation therapy using sealed sources of ionizing radiation was carried out.

Two methodologically different approaches to dosimetric planning of the level of internal irradiation from a radiopharmaceutical introduced into the patient’s body are considered.

The features of radiation monitoring are discussed both for the patient’s stay in the radionuclide therapy department and his/her safe discharge from the department for others, and for the removed solid and liquid radioactive waste.

A comparative analysis of the functional capabilities of various criteria for assessing the long-term and short-term effectiveness of radionuclide therapy of bone metastases was carried out. Focal absorbed doses of internal irradiation are considered as one of the criteria, for the determination of which a method for their calculation is proposed based on the MIRD formalism and quantitative data from SPECT/CT scanning of an X-ray phantom and a real patient who has been administered a β-γ-emitting therapeutic radiopharmaceutical.

Results: Using a clinical example of radionuclide therapy with ¹⁷⁷Lu-PSMA-617 in a patient with stage 4 prostate cancer, dose estimates of internal irradiation of bone metastases by β-particles were obtained. The obtained dosimetric data were compared with efficiency estimates based on metabolic, hematological, hormonal and biochemical parameters, as well as the tumor marker PSA.

Conclusion: Unlike conventional radiation therapy, dosimetric support for planning and evaluating the effectiveness of treatment has not yet become a fundamental methodological basis for modern radionuclide therapy.

Keywords: radionuclide therapy, dosimetric monitoring, treatment planning, radiation monitoring, treatment effectiveness

For citation: Narkevich BYa. Is Dosimetry Necessary in Radionuclide Therapy of Patients with Metastases? Medical Radiology and Radiation Safety. 2026;71(2):81–92. (In Russian). DOI:10.33266/1024-6177-2026-71-2-81-92

References

1. Gleisner K.S., Chouin N., Gabina P.M., et al. EANM Dosimetry Committee Recommendations for Dosimetry of 177Lu‑labelled Somatostatin‑Receptor ‑ and PSMA‑Targeting Ligands. Eur J Nucl Med Mol Imaging. 2022;49:1778–809. Doi.: 10.1007/S00259-022-05727-7.
2. Kratochwil C., Fendler W.P., Eiber M., et al. Joint EANM/SNMMI Procedure Guideline for the Use of 177Lu‑labeled PSMA‑Targeted Radioligand‑Therapy (177Lu‑PSMA‑RLT).  Eur J Nucl Med Mol Imaging. 2023;50:2830–45. Doi: 10.1007/S00259-023-06255-8.
3. Sgouros G., Bodei L., McDevitt M.R., Nedrow J.R. Radiopharmaceutical Therapy in Cancer: Clinical Advances and Challenges. Nature Reviews: Drug Discovery. 2020;19:589-608.
4. Narkevich B.Ya., Dolgushin M.B., Krylov V.V., Meshcheryakova N.A., Nevzorov D.I. Functional Optimization of Radionuclide Pairs in Prostate Cancer Theranostics. Onkologicheskiy Zhurnal: Luchevaya Diagnostika, Luchevaya Terapiya = Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2020;3;1:38-56 (In Russ.).
5. ICRU Report 96. Dosimetry-Guided Radiopharmaceutical Therapy. Journal of ICRU. 2021;21:1. Doi: 10.1177/14736691211060117.
6. Bentzen S.M., Constine L.S., Deasy J.O., et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an Introduction to the Scientific Issues. Int J Radiat Oncol Biol Phys. 2010;76;3.Suppl:S1–S160.
7. Narkevich B.Ya., Dolgushin B.I. Radiation Safety in Interventional Radiology. Ed. Dolgushin B.I. Interventsionnaya Radiologiya v Onkologii = Interventional Radiology in Oncology. National Guidelines. Moscow, Vidar-M Publ., 2022. P. 51-66 (In Russ.).
8. Sanitary and Epidemiological Requirements for Radiation Safety of the Population when Handling Ionizing Radiation Sources. SanPiN 2.6.4115–25. (In Russ.).
9. Sanitary Rules for Handling Radioactive Waste (SPORO-2002) (as Amended and Supplemented on September 16, 2013) (In Russ.).
10. Narkevich B.Ya. Current Issues of Radioactive Waste Management in Nuclear Medicine. Radioaktivnyye Otkhody = Radioactive Waste. 2022;1:28-37 (In Russ.).
11. Narkevich B.Ya., Ryzhov S.A., Geliashvili T.M., Smirnov G.Yu. Technologies for the Removal of Liquid Radioactive Waste in Radionuclide Therapy Departments. Meditsinskaya Fizika = Medical Physics. 2024;3:52-64 (In Russ.).
12. Rosciyskiye Klinicheskiye Rekomendatsii po Diagnostike i Lecheniyu Limfoproliferativnykh Zabolevaniy = Russian Clinical Guidelines for the Diagnosis and Treatment of Lymphoproliferative Diseases. Ed. by Poddubnaya I.V., Savchenko V.G. Moscow, MediaMedika Publ., 2014. 324 p. (In Russ.).
13. Gelezhe P.V., Morozov S.P., Mandel’blat Yu.E., Libson Ye.I. What’s New in the Criteria for Assessing Oncological Diseases in Radiation Diagnostics: RECIST vs. PERCIST. Luchevaya Diagnostika i Terapiya = Diagnostic Radiology and Radiotherapy. 2014;2:28–36 (In Russ.).
14. Narkevich B.Ya., Krylov A.S., Ryzhkov A.D. Simplified Method for Calculating Internal Irradiation Doses of Bone Metastases during Radionuclide Therapy. Meditsinskaya Fizika = Medical Physics. 2023;1:48-57 (In Russ.).
15. Chipiga L.A., Lavreshov D.D., Vodovatov A.V., et al. Experimental Assessment of Absorbed Doses in Pathological Foci during Radionuclide Therapy with 225Ac-PSMA-617 and 225Ac-DOTA-TATE. Meditsinskaya Fizika = Medical Physics. 2023;4:40-50 (In Russ.).

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The author declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. The article was prepared with the author’s participation.

Article received: 20.01.2026. Accepted for publication: 25.02.2026.